Key result
Daily intake of Met-Lys-Pro for 24 weeks did not significantly improve total ADAS-cog scores compared to placebo in adults without dementia, though orientation subscores improved (P=0.022).
Why the study?
Met-Lys-Pro (MKP) attenuated cognitive decline in a mouse model of Alzheimer’s disease, but its effect on cognitive function improvement in humans remained unknown.
Does Met-Lys-Pro (MKP) improve cognitive function in community-dwelling adults without dementia?
RCT (n=268)
Double-blind
randomly allocated
Does Met-Lys-Pro (MKP) improve cognitive function in community-dwelling adults without dementia?
In adults without dementia, daily intake of the casein-derived peptide MKP for 24 weeks did not significantly improve overall cognitive function, though it was safe and showed potential benefits in orientation.
Background: Preventative measures have recently been taken to reduce the incidence of Alzheimer’s disease worldwide. We previously showed that Met-Lys-Pro (MKP), a casein-derived angiotensin-converting enzyme inhibitory peptide with the potential to cross the blood–brain barrier, attenuated cognitive decline in a mouse model of Alzheimer’s disease. However, the effect of MKP on cognitive function improvement in humans remains unknown. This exploratory study sought to investigate whether MKP intake could improve cognitive function in adults without dementia. Methods: A total of 268 community-dwelling adults without dementia participated in this 24-week randomized controlled trial. Participants were randomly allocated to the MKP (n = 134) or placebo (n = 134) group. The MKP group received four tablets daily, each containing 50 μg MKP, while the placebo group received four dextrin tablets containing no detectable MKP for 24 weeks. Scores on the Japanese version of the cognitive subscale of the Alzheimer’s Disease Assessment Scale (ADAS-cog) were used as the primary outcome to compare cognitive function between the MKP and placebo groups. The study products were also evaluated for safety. Results: The intention-to-treat analysis showed that there was no significant difference between the groups in terms of the ADAS-cog total score. Orientation, as measured by the respective ADAS-cog subscale, was significantly improved compared to placebo at 24 weeks post-MKP administration ( P = 0.022). No serious adverse events due to MKP intake were observed. Conclusion: To the best of our knowledge, this is the first study to report the effects of MKP on human cognition. These preliminary results suggested the safety of daily MKP intake and its potential to improve orientation in adults without dementia. Further clinical studies are needed to confirm the present findings and the benefits of MKP on cognitive function.
No takes yet. Share an insight, caveat, or question.
Yuda et al. (2020) conducted an RCT in adults without dementia (n=268). Met-Lys-Pro (MKP) vs. placebo was evaluated on ADAS-cog total score. Daily intake of Met-Lys-Pro for 24 weeks did not significantly improve total ADAS-cog scores compared to placebo in adults without dementia, though orientation subscores improved (P=0.022).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: